智通财经APP讯，三生制药(01530)发布公告，于2025年10月20日(交易时段后)，作为集团激励其董事、 高级管理层及雇员表现措施的一部分，公司全资附属公司Mandi Inc.的董事会已决议按每股 Mandi股份 1.0美元的代价向选定参与者发行640股Mandi股份作为奖励，其中290股 Mandi股份将根据Mandi股权激 励计划发行予该信托的控股公司Mandi Group Limited 及350股Mandi股份将发行予Hero Grand。向Hero Grand及Mandi Group Limited发行Mandi 股份的代价乃经考虑(其中包括)选定参与者过往对Mandi及集团 作出的贡献后厘定。 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 文 件 之 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 文 件 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 本公司一家附屬公司根據其股權激勵計劃授出獎勵股份 於二零二五年十月二十日（交 易 時 段 後），作 為 本 集 團 激 勵 其 董 事、高 級 管 理 層 及 僱 員 表 現 措 施 的 一 部 分，本 公 司 全 資 附 屬 公 司Mandi Inc.的董事會已決議按每股 Mandi股 份1.0美元的代價向選定參與者發行640股Mandi股 份 作 為 獎 勵，其 中290股 Mandi股份將根據Mandi股權激勵計劃發行予該信託的控股公司Mandi Group Limited 及350股Mandi股份將發行予Hero Grand。向Hero Grand及Mandi Group Limited發 行Mandi 股份的代價 ...

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed down 0.46% on October 20, with a trading volume of 907 million yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of October 17, 2024, the fund's shares totaled 8.134 billion, with a total size of 6.968 billion yuan, reflecting a significant increase in both shares and size compared to the previous year [1] Fund Performance - The fund has seen a remarkable increase of 1957.27% in shares and 1744.35% in size since December 31, 2023 [1] - The fund's cumulative trading amount over the last 20 trading days reached 27.487 billion yuan, with an average daily trading amount of 1.374 billion yuan [1] - Year-to-date, the cumulative trading amount is 224.063 billion yuan, averaging 1.173 billion yuan per day over 191 trading days [1] Fund Management - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 71.34% during the management period [2] - The fund's top holdings include companies such as Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant percentages of the portfolio allocated to these stocks [2]

Group 1: Stock Recommendations - 吉利汽车 (Geely Auto) has a target price of HKD 32.00, with a current market value of USD 24.8 billion and a PE ratio of 19.01[5] - 零跑汽车 (Leap Motor) is rated as a buy with a target price of HKD 80.00, showing a potential upside of 35%[5] - 极兔速递 (J&T Express) has a target price of HKD 58.00, with a market value of USD 11.7 million and a PE ratio of 11.7[5] Group 2: Performance Overview - The basket of 25 stocks listed in the previous report had an average return of -3.9%, compared to the MSCI China Index return of -3.6%[10] - Out of the 25 stocks, 11 stocks outperformed the benchmark index[10] - The report includes a total of 25 long positions, indicating a diverse investment strategy[10]

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2][47]. Core Insights - The report highlights that the medical device procurement is gradually reflecting principles of "stabilizing clinical needs, ensuring quality, preventing collusion, and countering price wars" [6][30]. - The report suggests that the recent adjustments in procurement rules indicate a shift towards a more moderate approach, focusing on clinical needs and product quality rather than solely on low prices [6][30]. - The report emphasizes the potential for long-term development in the domestic medical device industry as procurement becomes more reasonable [6][30]. Summary by Sections Industry Overview - The closing index for the medical and biological sector is 8583.87, with a 52-week high of 9323.49 and a low of 6764.34 [2]. Market Performance - During the week of October 13-17, 2025, the A-share medical and biological sector fell by 2.48%, underperforming the CSI 300 index by 0.26 percentage points but outperforming the ChiNext index by 3.23 percentage points [7][36]. - The Hang Seng Healthcare Index decreased by 5.85%, underperforming the Hang Seng Index by 1.88 percentage points [7][36]. Industry Opinions and Investment Recommendations 1. **Innovative Drugs**: The innovative drug sector is experiencing adjustments, with a recommendation to maintain or increase positions based on long-term industry development logic. Key companies to watch include Innovent Biologics, 3SBio, and others [8][21]. 2. **Medical Devices**: The report notes that the National Medical Insurance Administration's recent procurement documents aim to optimize price differences and control "anchor points," indicating a move away from simply selecting the lowest bid [8][29]. 3. **Research Services**: The report expresses optimism about investment opportunities in the research services sector, particularly for companies with strong competitive advantages [26]. Sector Valuation - As of October 17, 2025, the overall valuation of the medical sector (TTM) is 30.03, a decrease of 0.84 from the previous week. The sector's valuation premium over the CSI 300 index is 123.96%, down by 4.90 percentage points [43].

Macro and Strategy Research - The establishment of the Beijing Stock Exchange (BSE) in 2021 aimed to support the innovative development of small and medium-sized enterprises, resulting in 278 listed companies by 2025, with nearly 80% being small and micro enterprises and 88% being private enterprises. 72% of these companies belong to specialized and innovative sectors. In the first half of 2025, these companies achieved a total operating income of 93.35 billion yuan and a net profit attributable to shareholders of 6.12 billion yuan, with 61.5% of companies reporting revenue growth and 50.4% reporting net profit growth year-on-year [2][3]. - Despite the economic challenges of strong supply and weak demand, the BSE has shown a trend of "increasing revenue without increasing profit," with a year-on-year revenue growth rate in Q2 2025 continuing the positive growth trend since Q4 2024. However, net profit attributable to shareholders has been in continuous decline since Q4 2022, with Q2 2025 also reflecting this trend. The return on equity showed marginal improvement due to seasonal recovery in total asset turnover and leverage effects [3]. - In terms of industry performance, the upstream resource sectors showed a year-on-year decline in net profit growth, consistent with the overall trends in the A-share market. In the midstream materials sector, the basic chemical industry experienced negative growth, while the construction materials industry achieved positive growth. The construction decoration industry in the midstream manufacturing sector outperformed its A-share counterparts, while sectors like electric equipment and machinery showed negative growth. In the consumer sectors, BSE companies in beauty care and automotive performed better than their A-share counterparts, while in essential consumption, textile and apparel companies exceeded overall industry performance [3]. - Overall, BSE companies, which have a high concentration of specialized and innovative small and medium enterprises, have significant competitive differentiation in consumer sectors like beauty care and textiles. Additionally, by focusing on niche markets, BSE companies in the construction decoration sector have shown performance that exceeds industry cycles [4]. Fixed Income Research - The issuance of ultra-long special government bonds has been completed, with a total of 48 bonds issued during the period from October 10 to October 16, 2025, amounting to 625.2 billion yuan in total issuance and a net financing amount of 155.3 billion yuan. As of October 16, 2025, 37 billion yuan of new local special bonds have been issued, and 13 billion yuan of ultra-long special government bonds have been issued, completing the annual issuance plan [12][13]. - The bond yield curve has flattened slightly, with the 10-year government bond yield showing a fluctuating pattern. The relationship between stock and bond markets has become more correlated, with major stock indices and government bond yields moving in tandem [13]. Industry Research - Recent developments in the pharmaceutical and biotechnology sector include the signing of a licensing agreement between Hansoh Pharmaceutical and Roche, as well as various approvals and notifications from the National Medical Insurance Administration regarding reforms and pilot programs in traditional Chinese medicine [15]. - The overall performance of the pharmaceutical and biotechnology sector has seen a decline, with the Shanghai Composite Index dropping by 0.45% and the Shenzhen Component Index falling by 4.66%. The pharmaceutical sector specifically decreased by 2.12%, with most sub-sectors experiencing declines [15][16]. - Looking ahead, the upcoming European Society for Medical Oncology (ESMO) annual meeting is expected to provide investment opportunities through the disclosure of research results from innovative Chinese pharmaceutical companies. The third-quarter earnings reporting period is also anticipated to show gradual improvements in fundamentals, particularly in sectors benefiting from optimized procurement rules [16].

Investment Rating - The report maintains a rating of "Buy" for the pharmaceutical and biotechnology sector, specifically recommending companies like Zhaoli Pharmaceutical and Fangsheng Pharmaceutical as undervalued high-dividend Chinese medicine stocks [1]. Core Insights - The report highlights that the Chinese medicine sector is characterized by strong cash flow and low debt ratios, making it capable of high dividend payouts. This sector is less affected by international political dynamics, making it a viable defensive strategy in a volatile market [16][17]. - The report ranks sub-sectors in the following order of preference: innovative drugs > research services > CXO > Chinese medicine > medical devices > pharmacies [10][12]. Summary by Sections 1. Significant Excess Returns in Pharmaceutical Stocks - The A-share pharmaceutical index has shown a year-to-date increase of 18.85%, with a weekly decline of 2.48%. The Chinese medicine sector saw a slight increase of 0.38%, while other sectors like medical services and medical devices experienced declines [4][9]. 2. High Dividend Yield in Chinese Medicine Sector - The report emphasizes the attractiveness of high dividend yields in the Chinese medicine sector, with companies like Zhaoli Pharmaceutical expected to have a dividend yield of 4.1% in 2025, and Fangsheng Pharmaceutical at 3.1% [17][18]. 3. R&D Progress and Company Dynamics - Recent developments include the approval of innovative drugs and clinical trials by various companies, indicating ongoing advancements in the sector [4][12]. 4. Industry and Regulatory Insights - The report provides insights into the regulatory landscape affecting the pharmaceutical industry, noting that the impact of tariff wars on the sector is limited [4]. 5. Market Review - The report tracks the performance of various pharmaceutical sub-sectors, noting that the Chinese medicine sector has outperformed others in recent weeks [4][9].

Investment Rating - The report maintains an investment rating of "Outperform" for the biopharmaceutical sector [8]. Core Insights - The report highlights several catalysts for the sector, including academic conferences, business development (BD) achievements, medical insurance negotiations, and innovative drug directories from commercial insurance [21]. - Key companies to watch include: 1. Products with high certainty for overseas expansion certified by MNCs: PD-1 upgraded products from Sanofi and GLP-1 assets from Federal Pharmaceuticals [21]. 2. Potential blockbuster products for overseas licensing from MNCs: PD-1 upgraded products from Kangfang Biotech and Innovent Biologics, breakthroughs in autoimmune fields from Yifang Biotech and China Antibody, and innovative target ADCs from Fuhong Hanlin and Shiyao Group [21]. 3. Companies likely to benefit from medical insurance negotiations and innovative drug directories: Heng Rui Medicine, Kangnuo Pharmaceutical, Maiwei Biotech, Zhixiang Jintai, and Haichuang Pharmaceutical [21]. Summary by Sections Weekly New Drug Market Review - From October 13 to October 19, 2025, the top five gainers in the new drug sector were: - Sanofi National Health (+12.68%) - Kangning Jereh (+10.18%) - Rongchang Biotech (+5.42%) - Xiansheng Pharmaceuticals (+4.88%) - Qianyan Biotech (+3.77%) - The top five losers were: - Yongtai Biotech (-29.76%) - Betta Pharmaceuticals (-16.98%) - Yiming Oncology (-16.80%) - Deqi Pharmaceuticals (-15.30%) - WuXi Biologics (-13.43%) [4][16]. New Drug Industry Focus Analysis - Recently, Bai Li Tianheng presented overseas multi-center solid tumor research data for its EGFR×HER3 dual antibody ADC drug, iza-bren, at the 2025 European Society for Medical Oncology (ESMO) annual meeting. The data showed consistent efficacy and safety across different populations, confirming the broad-spectrum tumor-killing efficacy of iza-bren [21][24]. New Drug Approval and Acceptance - This week, one new drug or new indication application was approved, and 13 new drug or new indication applications were accepted in China [9][27]. - Additionally, 30 new drug clinical applications were approved, and 47 new drug clinical applications were accepted [10][30].

A-shares Market Valuation - The current PE (TTM) for the A-share market is 16.51, with a median of 13.48 and a maximum of 30.60[8] - The PE (TTM) excluding financials and oil & gas is 25.31, indicating a higher valuation compared to the overall market[6] - The Shanghai Composite Index has a PE (TTM) of 14.21, while the ChiNext Index stands at 41.35[8] Hong Kong Market Valuation - The Hang Seng Index has a current PE (TTM) of 11.61, with a median of 10.28 and a maximum of 22.67[59] - The Hang Seng Technology Index shows a higher valuation with a current PE (TTM) of 22.13[63] - The Hang Seng China Enterprises Index has a PE (TTM) of 10.47, reflecting a lower valuation compared to other indices[63] US Market Valuation - The S&P 500 Index has a current PE (TTM) of 29.34, with a median of 21.09 and a maximum of 41.99[82] - The NASDAQ Index shows a PE (TTM) of 42.87, indicating a high growth expectation[90] - The Dow Jones Industrial Average has a PE (TTM) of 31.27, reflecting a stable valuation compared to other indices[94] Sector Valuation Insights - In the A-share market, the food and beverage sector has a low PE (TTM) while the technology sector shows a high PE, indicating sector-specific valuation disparities[22] - The financial sector, particularly banks and brokers, has a PB (LF) of 0.91, suggesting undervaluation compared to historical averages[101] - The consumer sector, including liquor and pharmaceuticals, shows varied PE levels, with liquor at 18.94 and pharmaceuticals at 38.08[32]

Core Viewpoint - Hong Kong Futures Exchange plans to launch futures contracts based on the Hang Seng Biotechnology Index on November 28, 2025, pending regulatory approval [1] Group 1: Futures Contract Details - The futures contract will be based on the Hang Seng Biotechnology Index, which tracks the 30 largest biotechnology companies listed in Hong Kong [1] - The contract code will be HBI, with each index point valued at 50 HKD, resulting in a contract value of approximately 776,000 HKD based on the closing price on October 14, 2025 [3] - The contract will have monthly, quarterly, and subsequent quarterly expirations, with cash settlement in HKD [3] Group 2: ETF Performance and Characteristics - The Hang Seng Biotechnology ETF (513280) has a management fee of 0.15% per year and has seen a significant net inflow of funds, with a year-to-date share growth rate of 24% [1][4] - The ETF's underlying index has a high concentration in innovative drugs (69%) and CXO (over 20%), providing exposure to high-growth sectors [4][6] - The index has shown a remarkable return of 79.67% over the past year, with the ETF outperforming the index with a return of 80.9% [6][10] Group 3: Market Context and Trends - The introduction of the Hang Seng Biotechnology Index futures reflects the growing importance of the biotechnology sector, paralleling the Hang Seng Technology Index [2] - The biotechnology sector is described as the fastest-growing and most dynamic segment in the market, indicating strong investor interest and potential for future growth [1][2] - Analysts are optimistic about the long-term trends in innovative drugs and the overall health of Hong Kong's pharmaceutical companies, supported by stable cash flows and robust R&D pipelines [9]